Уважаемые пользователи!

Данный сайт содержит информацию для людей с медицинским образованием и специалистов здравоохранения.
Входя на сайт, Вы подтверждаете свое согласие с Условиями использования и Политикой конфиденциальности.

Dear visitor!
This site contains medical information for healthcare professionals.
You can go further, if you agree with Terms and Conditions and Privacy Policy on this site.

The consensus recommendations of a group of international experts on the fundamental concepts related to the issues of testosterone deficiency and its treatment.


Conference on the development of the international expert consensus to address frequently asked questions related to a medical condition of testosterone deficiency (TD, male hypogonadism) and testosterone therapy was held in Prague (Czech Republic) on October 1, 2015. The included experts were representatives from a variety of medical specialties, including urology, endocrinology, diabetology, internal medicine, as well as representatives of basic medical sciences. An international team of experts came to the following conclusions: TD - an important medical condition that affects the health and well-being of men; TD symptoms is a consequence of low testosterone levels, regardless of whether background etiology installed; TD consequences are global; care must be taken in an attempt to use any uniform threshold levels of testosterone for a decision on the appointment of testosterone therapy; a person does not have any reason to refrain from appointing testosterone therapy only on the basis of age; the existing evidence does not suggest increasing the prostate cancer or cardiovascular disease risk during testosterone therapy; there is evidence conserning the feasibility of a major research initiative to explore possible cardioprotective beneficial effects of testosterone therapy in men with metabolic disorders, including diabetes.

Abraham Morgentaler

Men’s Health Boston and Harvard Medical School

Author for correspondence.
Email: amorgent@yahoo.com

United States MD

M. Zitzmann

Центр репродуктологии и андрологии, Мюнстерская университетская клиника, г. Мюнстер, Германия

Email: amorgent@yahoo.com


A. M. Traish

кафедра биохимии и кафедра урологии, медицинская школа Бостонского университета, штат Массачусетс, США

Email: amorgent@yahoo.com

United States

A. W. Fox

группа фармацевтической медицины, Институт фармацевтических исследований, факультет биомедицинских исследований, Лондонский королевский колледж, г. Лондон, Англия

Email: amorgent@yahoo.com

United Kingdom

T. H. Jones

диабетологический и эндокринологический центр Robert Hague, клиника Barnsley национальной службы здравоохранения, г. Барнсли, Великобритания

Email: amorgent@yahoo.com

United Kingdom

M. Maggi

кафедра медицинской сексологии и андрологии, Флорентийский университет, г. Флоренция, Италия

Email: amorgent@yahoo.com


S. Arver

медицинский факультет с центром андрологии и медицинской сексологии, университетская клиника Karolinska, г. Стокгольм, Швеция

Email: amorgent@yahoo.com


A. Aversa

университет Magna Grecia, г. Катанцаро, Италия

Email: amorgent@yahoo.com


J.C.N. Chan

Гонконгский институт изучения сахарного диабета и ожирения, китайский университет Гонконга, г. Гонконг

Email: amorgent@yahoo.com

Taiwan, Province of China

A. S. Dobs

медицинская школа при университете Джона Хопкинса, г. Балтимор, штат Мэриленд, США

Email: amorgent@yahoo.com

United States

G. I. Hackett

клиника Доброй Надежды, г. Саттон Колдфилд, Великобритания

Email: amorgent@yahoo.com

United Kingdom

W. J. Hellstrom

андрологическое подразделение кафедры урологии, медицинская школа университета Tulane, г. Новый Орлеан, штат Луизиана, США

Email: amorgent@yahoo.com

United States

P. Lim

клиника Gleneagles, г. Сингапур, и Военно-морская медицинская академия, Индонезия

Email: amorgent@yahoo.com


B. Lunenfeld

биомедицинский факультет университета Bar Ilan, г. Рамат-Ган, Израиль

Email: amorgent@yahoo.com


G. Mskhalaya

отделение андрологии, центр медицинской репродуктологии MAMA, г. Москва, Российская Федерация

Email: amorgent@yahoo.com

Russian Federation

C. C. Schulman

кафедра урологии, клиника Erasme, г. Брюссель, Бельгия

Email: amorgent@yahoo.com


L. O. Torres

г. Белу-Оризонти, Minas Gerais, Бразилия (L.O.T.).

Email: amorgent@yahoo.com


  1. Vigen R. Association of Testosterone Therapy With Mortality, Myocardial Infarction, and Stroke in Men With Low Testosterone Levels. JAMA. 2013;310(17):1829. doi: 10.1001/jama.2013.280386.
  2. Gong Y, Finkle WD, Greenland S, et al. Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Therapy Prescription in Men. PLoS ONE. 2014;9(1):e85805. doi: 10.1371/journal.pone.0085805.
  3. Morgentaler A, Zitzmann M, Traish AM, Fox A. International expert consensus conference on testosterone deficiency and its treatment held in Prague, Czech Republic. The Aging Male. 2015;18(4):205-206. doi: 10.3109/13685538.2015.1106469.
  4. Aub JC. Endocrines: The Use of Testosterone. N Engl J Med. 1940;222(21):877-881. doi: 10.1056/nejm194005232222104.
  5. Baillargeon J, Urban RJ, Ottenbacher KJ, et al. Trends in Androgen Prescribing in the United States, 2001 to 2011. JAMA Internal Medicine. 2013;173(15):1465. doi: 10.1001/jamainternmed.2013.6895.
  6. Morgentaler A. Testosterone and Prostate Cancer: An Historical Perspective on a Modern Myth. Eur Urol. 2006;50(5):935-939. doi: 10.1016/j.eururo.2006.06.034.
  7. Overselling testosterone, dangerously [editorial]. New York Times Available at http://www.nytimes.com/2014/02/05/opinion/overselling-testosterone-dangerously.html?_r1/40.
  8. Nguyen CP, Hirsch MS, Moeny D, et al. Testosterone and “Age-Related Hypogonadism” — FDA Concerns. N Engl J Med. 2015;373(8):689-691. doi: 10.1056/NEJMp1506632.
  9. PRAC review does not confirm increase in heart problems with testosterone medicines: committee recommends medicines can continue to be given for their authorised uses [pressrelease]. European Medicines Agency Available at http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/10/WC500175207.pdf.
  10. Ministry of Health, Singapore Available at https://www.moh.gov.sg/content/moh_web/home.html.file. Circular 12-3-2015.
  11. Wu FCW, Tajar A, Beynon JM, et al. Identification of Late-Onset Hypogonadism in Middle-Aged and Elderly Men. N Engl J Med. 2010;363(2):123-135. doi: 10.1056/NEJMoa0911101.
  12. Laaksonen DE, Niskanen L, Punnonen K, et al. Testosterone and Sex Hormone-Binding Globulin Predict the Metabolic Syndrome and Diabetes in Middle-Aged Men. Diabetes Care. 2004;27(5):1036-1041. doi: 10.2337/diacare.27.5.1036.
  13. Antonio L, Wu FCW, O’Neill TW, et al. Associations Between Sex Steroids and the Development of Metabolic Syndrome: A Longitudinal Study in European Men. J Clin Endocrinol Metab. 2015;100(4):1396-1404. doi: 10.1210/jc.2014-4184.
  14. Ohlsson C, Barrett-Connor E, Bhasin S, et al. High Serum Testosterone Is Associated With Reduced Risk of Cardiovascular Events in Elderly Men. J Am Coll Cardiol. 2011;58(16):1674-1681. doi: 10.1016/j.jacc.2011.07.019.
  15. Behre HM, Tammela TLJ, Arver S, et al. A randomized, double-blind, placebo-controlled trial of testosterone gel on body composition and health-related quality-of-life in men with hypogonadal to low-normal levels of serum testosterone and symptoms of androgen deficiency over 6 months with 12 months open-label follow-up. The Aging Male. 2012;15(4):198-207. doi: 10.3109/13685538.2012.699562.
  16. Morgentaler A, Miner MM, Caliber M, et al. Testosterone Therapy and Cardiovascular Risk: Advances and Controversies. Mayo Clin Proc. 2015;90(2):224-251. doi: 10.1016/j.mayocp.2014.10.011.
  17. Wu FCW, Tajar A, Pye SR, et al. Hypothalamic-Pituitary-Testicular Axis Disruptions in Older Men Are Differentially Linked to Age and Modifiable Risk Factors: The European Male Aging Study. J Clin Endocrinol Metab. 2008;93(7):2737-2745. doi: 10.1210/jc.2007-1972.
  18. Grossmann M. Low Testosterone in Men with Type 2 Diabetes: Significance and Treatment. J Clin Endocrinol Metab. 2011;96(8):2341-2353. doi: 10.1210/jc.2011-0118.
  19. Corona G, Maggi M. Perspective: Regulatory Agencies’ Changes to Testosterone Product Labeling. The Journal of Sexual Medicine. 2015;12(8):1690-1693. doi: 10.1111/jsm.12951.
  20. Snyder PJ, Bhasin S, Cunningham GR, et al. Effects of Testosterone Treatment in Older Men. N Engl J Med. 2016;374(7):611-624. doi: 10.1056/NEJMoa1506119.
  21. Traish AM, Miner MM, Morgentaler A, Zitzmann M. Testosterone Deficiency. Am J Med. 2011;124(7):578-587. doi: 10.1016/j.amjmed.2010.12.027.
  22. Zarotsky V, Huang M-Y, Carman W, et al. Systematic Literature Review of the Epidemiology of Nongenetic Forms of Hypogonadism in Adult Males. Journal of Hormones. 2014;2014:1-17. doi: 10.1155/2014/190347.
  23. Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2008;60(7):762-769. doi: 10.1111/j.1742-1241.2006.00992.x.
  24. Araujo AB, O’Donnell AB, Brambilla DJ, et al. Prevalence and Incidence of Androgen Deficiency in Middle-Aged and Older Men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2004;89(12):5920-5926. doi: 10.1210/jc.2003-031719.
  25. Araujo AB, Esche GR, Kupelian V, et al. Prevalence of Symptomatic Androgen Deficiency in Men. J Clin Endocrinol Metab. 2007;92(11):4241-4247. doi: 10.1210/jc.2007-1245.
  26. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal Effects of Aging on Serum Total and Free Testosterone Levels in Healthy Men. J Clin Endocrinol Metab. 2001;86(2):724-731. doi: 10.1210/jcem.86.2.7219.
  27. Moskovic DJ, Araujo AB, Lipshultz LI, Khera M. The 20-Year Public Health Impact and Direct Cost of Testosterone Deficiency in U.S. Men. The Journal of Sexual Medicine. 2013;10(2):562-569. doi: 10.1111/j.1743-6109.2012.02944.x.
  28. Hall SA. Treatment of Symptomatic Androgen DeficiencyResults From the Boston Area Community Health Survey. Arch Intern Med. 2008;168(10):1070. doi: 10.1001/archinte.168.10.1070.
  29. Corona G, Isidori AM, Buvat J, et al. Testosterone Supplementation and Sexual Function: A Meta-Analysis Study. The Journal of Sexual Medicine. 2014;11(6):1577-1592. doi: 10.1111/jsm.12536.
  30. Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174(3):R99-R116. doi: 10.1530/eje-15-0262.
  31. Corona G, Maseroli E, Maggi M. Injectable testosterone undecanoate for the treatment of hypogonadism. Expert Opin Pharmacother. 2014;15(13):1903-1926. doi: 10.1517/14656566.2014.944896.
  32. Saad F, Haider A, Doros G, Traish A. Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity. 2013;21(10):1975-1981. doi: 10.1002/oby.20407.
  33. Corona G, Vignozzi L, Sforza A, et al. Obesity and late-onset hypogonadism. Mol Cell Endocrinol. 2015;418:120-133. doi: 10.1016/j.mce.2015.06.031.
  34. Isidori AM, Balercia G, Calogero AE, et al. Outcomes of androgen replacement therapy in adult male hypogonadism: recommendations from the Italian society of endocrinology. J Endocrinol Invest. 2014;38(1):103-112. doi: 10.1007/s40618-014-0155-9.
  35. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone Therapy in Men with Androgen Deficiency Syndromes: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95(6):2536-2559. doi: 10.1210/jc.2009-2354.
  36. Zitzmann M, Faber S, Nieschlag E. Association of Specific Symptoms and Metabolic Risks with Serum Testosterone in Older Men. J Clin Endocrinol Metab. 2006;91(11):4335-4343. doi: 10.1210/jc.2006-0401.
  37. Hackett G, Cole N, Bhartia M, et al. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study). Int J Clin Pract. 2014;68(2):203-215. doi: 10.1111/ijcp.12235.
  38. Zitzmann M. Mechanisms of Disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nature Clinical Practice Urology. 2007;4(3):161-166. doi: 10.1038/ncpuro0706.
  39. Schneider G, Nienhaus K, Gromoll J, et al. Aging males’ symptoms in relation to the genetically determined androgen receptor CAG polymorphism, sex hormone levels and sample membership. Psychoneuroendocrinology. 2010;35(4):578-587. doi: 10.1016/j.psyneuen.2009.09.008.
  40. Francomano D, Greco EA, Lenzi A, Aversa A. CAG Repeat Testing of Androgen Receptor Polymorphism: Is This Necessary for the Best Clinical Management of Hypogonadism? The Journal of Sexual Medicine. 2013;10(10):2373-2381. doi: 10.1111/jsm.12268.
  41. Zitzmann M, Nieschlag E. Androgen Receptor Gene CAG Repeat Length and Body Mass Index Modulate the Safety of Long-Term Intramuscular Testosterone Undecanoate Therapy in Hypogonadal Men. J Clin Endocrinol Metab. 2007;92(10):3844-3853. doi: 10.1210/jc.2007-0620.
  42. Stanworth RD, Akhtar S, Channer KS, Jones TH. The role of androgen receptor CAG repeat polymorphism and other factors which affect the clinical response to testosterone replacement in metabolic syndrome and type 2 diabetes: TIMES2 sub-study. Eur J Endocrinol. 2013;170(2):193-200. doi: 10.1530/eje-13-0703.
  43. Saad F, Yassin A, Haider A, et al. Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men. Korean Journal of Urology. 2015;56(4):310. doi: 10.4111/kju.2015.56.4.310.
  44. Bhasin S, Woodhouse L, Casaburi R, et al. Older Men Are as Responsive as Young Men to the Anabolic Effects of Graded Doses of Testosterone on the Skeletal Muscle. J Clin Endocrinol Metab. 2005;90(2):678-688. doi: 10.1210/jc.2004-1184.
  45. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of Testosterone on Muscle Strength, Physical Function, Body Composition, and Quality of Life in Intermediate-Frail and Frail Elderly Men: A Randomized, Double-Blind, Placebo-Controlled Study. J Clin Endocrinol Metab. 2010;95(2):639-650. doi: 10.1210/jc.2009-1251.
  46. Gray PB, Singh AB, Woodhouse LJ, et al. Dose-Dependent Effects of Testosterone on Sexual Function, Mood, and Visuospatial Cognition in Older Men. J Clin Endocrinol Metab. 2005;90(7):3838-3846. doi: 10.1210/jc.2005-0247.
  47. Lunenfeld B, Mskhalaya G, Zitzmann M, et al. Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. The Aging Male. 2015;18(1):5-15. doi: 10.3109/13685538.2015.1004049.
  48. Ullah MI, Washington T, Kazi M, et al. Testosterone Deficiency as a Risk Factor for Cardiovascular Disease. Horm Metab Res. 2011;43(03):153-164. doi: 10.1055/s-0030-1270521.
  49. Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169(6):725-733. doi: 10.1530/eje-13-0321.
  50. Shores MM, Smith NL, Forsberg CW, et al. Testosterone Treatment and Mortality in Men with Low Testosterone Levels. J Clin Endocrinol Metab. 2012;97(6):2050-2058. doi: 10.1210/jc.2011-2591.
  51. English KM, Steeds RP, Jones TH, et al. Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina: A Randomized, Double-Blind, Placebo-Controlled Study. Circulation. 2000;102(16):1906-1911. doi: 10.1161/01.cir.102.16.1906.
  52. English KM, Jones RD, Jones TH, et al. Testosterone acts as a coronary vasodilator by a calcium antagonistic action. J Endocrinol Invest. 2014;25(5):455-458. doi: 10.1007/bf03344037.
  53. Malkin CJ. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2005;27(1):57-64. doi: 10.1093/eurheartj/ehi443.
  54. Dhindsa S, Ghanim H, Batra M, et al. Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care. 2016;39(1):82-91. doi: 10.2337/dc15-1518.
  55. Allan CA, Strauss BJG, Burger HG, et al. Testosterone Therapy Prevents Gain in Visceral Adipose Tissue and Loss of Skeletal Muscle in Nonobese Aging Men. J Clin Endocrinol Metab. 2008;93(1):139-146. doi: 10.1210/jc.2007-1291.
  56. Traish AM. Outcomes of testosterone therapy in men with testosterone deficiency (TD): Part II. Steroids. 2014;88:117-126. doi: 10.1016/j.steroids.2014.05.004.
  57. Corona G, Maseroli E, Rastrelli G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. Expert Opin Drug Saf. 2014;13(10):1327-1351. doi: 10.1517/14740338.2014.950653.
  58. Baillargeon J, Urban RJ, Kuo YF, et al. Risk of Myocardial Infarction in Older Men Receiving Testosterone Therapy. Ann Pharmacother. 2014;48(9):1138-1144. doi: 10.1177/1060028014539918.
  59. Public Citizen petition denial response from FDA CDER to Public Citizen. Regulations. gov Available at. http://www. regulations.gov/#!documentDetail;D1/4;FDA-2014-P-0258-0003.
  60. Sharma R, Oni OA, Gupta K, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36(40):2706-2715. doi: 10.1093/eurheartj/ehv346.
  61. Anderson JL, May HT, Lappé DL, et al. Impact of Testosterone Replacement Therapy on Myocardial Infarction, Stroke, and Death in Men With Low Testosterone Concentrations in an Integrated Health Care System. The American Journal of Cardiology. 2016;117(5):794-799. doi: 10.1016/j.amjcard.2015.11.063.
  62. Baillargeon J, Urban RJ, Morgentaler A, et al. Risk of Venous Thromboembolism in Men Receiving Testosterone Therapy. Mayo Clin Proc. 2015;90(8):1038-1045. doi: 10.1016/j.mayocp.2015.05.012.
  63. Khera M, Crawford D, Morales A, et al. A New Era of Testosterone and Prostate Cancer: From Physiology to Clinical Implications. Eur Urol. 2014;65(1):115-123. doi: 10.1016/j.eururo.2013.08.015.
  64. Hormones E. Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies. JNCI Journal of the National Cancer Institute. 2008;100(3):170-183. doi: 10.1093/jnci/djm323.
  65. Cui Y, Zong H, Yan H, Zhang Y. The effect of testosterone replacement therapy on prostate cancer: a systematic review and meta-analysis. Prostate Cancer and Prostatic Disease. 2014;17(2):132-143. doi: 10.1038/pcan.2013.60.
  66. Baillargeon J, Kuo Y-F, Fang X, Shahinian VB. Long-term Exposure to Testosterone Therapy and the Risk of High Grade Prostate Cancer. The Journal of Urology. 2015;194(6):1612-1616. doi: 10.1016/j.juro.2015.05.099.
  67. Kaplan AL, Hu JC. Use of Testosterone Replacement Therapy in the United States and Its Effect on Subsequent Prostate Cancer Outcomes. Urology. 2013;82(2):321-326. doi: 10.1016/j.urology.2013.03.049.
  68. Cooper CS, Perry PJ, Sparks AET, et al. Effect of Exogenous Testosterone on Prostate Volume, Serum and Semen Prostate Specific Antigen Levels in Healthy Young Men. The Journal of Urology. 1998;159(2):441-443. doi: 10.1016/s0022-5347(01)63944-2.
  69. Morgentaler A, Traish AM. Shifting the Paradigm of Testosterone and Prostate Cancer: The Saturation Model and the Limits of Androgen-Dependent Growth. Eur Urol. 2009;55(2):310-321. doi: 10.1016/j.eururo.2008.09.024.
  70. Morgentaler A. Goodbye Androgen Hypothesis, Hello Saturation Model. Eur Urol. 2012;62(5):765-767. doi: 10.1016/j.eururo.2012.06.027.
  71. San Francisco IF, Rojas PA, DeWolf WC, Morgentaler A. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance. BJU Int. 2014;114(2):229-235. doi: 10.1111/bju.12682.
  72. Morgentaler A, Lipshultz LI, Bennett R, et al. Testosterone Therapy in Men With Untreated Prostate Cancer. The Journal of Urology. 2011;185(4):1256-1261. doi: 10.1016/j.juro.2010.11.084.
  73. Kacker R, Hult M, San Francisco I, et al. Can testosterone therapy be offered to men on active surveillance for prostate cancer? Preliminary results. Asian J Androl. 2016;18(1):16. doi: 10.4103/1008-682x.160270.
  74. Dohle GR, Arver S, Bettocchi C, Jones TH, Kliesch S, Punab M. Guidelines on Male Hypogonadism. European Association of Urology Available at http://uroweb.org/wp-content/uploads/18-Male-Hypogonadism_LR1.pdf.
  75. Emerging Risk Factors Collaboration. Diabetes Mellitus, Fasting Glucose, and Risk of Cause-Specific Death. N Engl J Med. 2011;364(9):829-841. doi: 10.1056/NEJMoa1008862.
  76. Ding EL, Song Y, Malik VS, Liu S. Sex Differences of Endogenous Sex Hormones and Risk of Type 2 Diabetes. JAMA. 2006;295(11):1288. doi: 10.1001/jama.295.11.1288.
  77. Cheung KKT, Luk AOY, So WY, et al. Testosterone level in men with type 2 diabetes mellitus and related metabolic effects: A review of current evidence. Journal of Diabetes Investigation. 2015;6(2):112-123. doi: 10.1111/jdi.12288.
  78. Dhindsa S, Prabhakar S, Sethi M, et al. Frequent Occurrence of Hypogonadotropic Hypogonadism in Type 2 Diabetes. J Clin Endocrinol Metab. 2004;89(11):5462-5468. doi: 10.1210/jc.2004-0804.
  79. Dhindsa S, Miller MG, McWhirter CL, et al. Testosterone Concentrations in Diabetic and Nondiabetic Obese Men. Diabetes Care. 2010;33(6):1186-1192. doi: 10.2337/dc09-1649.
  80. Jones TH. Testosterone deficiency: a risk factor for cardiovascular disease? Trends Endocrinol Metab. 2010;21(8):496-503. doi: 10.1016/j.tem.2010.03.002.
  81. Bjorntorp P. Metabolic Implications of Body Fat Distribution. Diabetes Care. 1991;14(12):1132-1143. doi: 10.2337/diacare.14.12.1132.
  82. Caminiti G, Volterrani M, Iellamo F, et al. Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure. J Am Coll Cardiol. 2009;54(10):919-927. doi: 10.1016/j.jacc.2009.04.078.
  83. Perls T, Handelsman DJ. Disease Mongering of Age-Associated Declines in Testosterone and Growth Hormone Levels. J Am Geriatr Soc. 2015;63(4):809-811. doi: 10.1111/jgs.13391.
  84. Basaria S, Harman SM, Travison TG, et al. Effects of Testosterone Administration for 3 Years on Subclinical Atherosclerosis Progression in Older Men With Low or Low-Normal Testosterone Levels. JAMA. 2015;314(6):570. doi: 10.1001/jama.2015.8881.
  85. Basaria S, Coviello AD, Travison TG, et al. Adverse Events Associated with Testosterone Administration. N Engl J Med. 2010;363(2):109-122. doi: 10.1056/NEJMoa1000485.
  86. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11(1). doi: 10.1186/1741-7015-11-108.
  87. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: world’s experts take unprecedented action to correct misinformation. The Aging Male. 2014;17(2):63-65. doi: 10.3109/13685538.2014.913413.
  88. Goodman N, Guay A, Dandona P, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on the Association of Testosterone and Cardiovascular Risk. Endocr Pract. 2015;21(9):1066-1073. doi: 10.4158/ep14434.ps.


Abstract - 1405

PDF (English) - 1159


Copyright (c) 2016 Моргенталер А., Цицман М., Трэйш А.М., Фокс А.В., Джонс Т.Х., Магги М., Арвер С., Аверса А., Чан Д.Н., Добс А.С., Хакетт Д., Хеллстром В.Д., Лим П., Люненфелд Б., Мсхалая Г.Ж., Шульман К.К., Торрес Л.О.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.